Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
文献类型：期刊论文
| 作者 | Gao, Jing1,2,5; Wang, Wei-qi1,4,5; Pei, Qing1,5; Lord, Megan S.3; Yu, Hai-jun1,5
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2020-04-21 |
| 页码 | 9 |
| 关键词 | cancer immunotherapy immunogenic cell death immunosuppressive tumor microenvironment nanomedicine drug delivery systems |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-020-0400-z |
| 通讯作者 | Yu, Hai-jun(hjyu@simm.ac.cn) |
| 英文摘要 | Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photothermal and photodynamic therapy, have been shown to elicit immunogenicity by inducing immunogenic cell death (ICD). However, ICD-based immunotherapy is restricted by the ITM limiting its efficacy in eliciting a long-term antitumor immune response, and by severe systemic toxicity. To address these challenges, nanomedicine-based drug delivery strategies have been exploited for improving cancer immunotherapy by boosting ICD of the tumor cells. Nanosized drug delivery systems are promising for increasing drug accumulation at the tumor site and codelivering ICD inducers and immune inhibitors to simultaneously elicit the immune response and relieve the ITM. This review highlights the recent advances in nanomedicine-based immunotherapy utilizing ICD-based approaches. A perspective on the clinical translation of nanomedicine-based cancer immunotherapy is also provided. |
| WOS关键词 | DRUG-DELIVERY SYSTEMS ; PHOTODYNAMIC THERAPY ; CALRETICULIN EXPOSURE ; CHECKPOINT BLOCKADE ; MOLECULAR-BASIS ; IMMUNE-SYSTEM ; NANOPARTICLES ; CHEMOTHERAPY ; INCREASES ; RECEPTOR |
| 资助项目 | National Natural Science Foundation of China[51873228] ; National Natural Science Foundation of China[31671024] ; National Natural Science Foundation of China[31900990] ; National Natural Science Foundation of China[81521005] ; Science and Technology Research Foundation of Shenzhen Bureau of Science and Technology Information[JCYJ20180227175420974] ; Youth Innovation Promotion Association of Chinese Academy of Sciences[2014218] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000528090300001 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280445]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Yu, Hai-jun |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Peking Univ, Shenzhen Inst, Shenzhen 518055, Peoples R China 3.Univ New South Wales, Grad Sch Biomed Engn, Sydney, NSW 2052, Australia 4.Nantong Univ, Sch Pharm, Nantong 226001, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Gao, Jing,Wang, Wei-qi,Pei, Qing,et al. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy[J]. ACTA PHARMACOLOGICA SINICA,2020:9. |
| APA | Gao, Jing,Wang, Wei-qi,Pei, Qing,Lord, Megan S.,&Yu, Hai-jun.(2020).Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.ACTA PHARMACOLOGICA SINICA,9. |
| MLA | Gao, Jing,et al."Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy".ACTA PHARMACOLOGICA SINICA (2020):9. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。